Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

NCT03234907 ·Status: COMPLETED ·Phase: PHASE3

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

NCT02913508 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320 ·Status: RECRUITING ·Phase: PHASE3

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

NCT03329209 ·Status: COMPLETED ·Phase: PHASE1

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NCT06045754 ·Status: RECRUITING ·Phase: PHASE4

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

NCT02038920 ·Status: COMPLETED ·Phase: PHASE3

Defining Predictors of RT Response to Vedolizumab in IBD

NCT03142321 ·Status: COMPLETED ·Phase: PHASE4

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT04738942 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

NCT02425111 ·Status: COMPLETED ·Phase: PHASE3

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice

NCT04890262 ·Status: COMPLETED

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

NCT03029143 ·Status: COMPLETED ·Phase: PHASE4

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910 ·Status: RECRUITING ·Phase: PHASE3

A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)

NCT02986724 ·Status: COMPLETED

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

NCT02620046 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF

NCT02820493 ·Status: WITHDRAWN ·Phase: PHASE4

A Study of Vedolizumab in Adults in Real-World Practice

NCT04872491 ·Status: COMPLETED

Characterization of CD Responders to Vedolizumab

NCT04909359 ·Status: COMPLETED

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

NCT02630966 ·Status: COMPLETED ·Phase: PHASE4

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

NCT00790933 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

NCT02249078 ·Status: WITHDRAWN ·Phase: PHASE1

A Study of Real-World Outcomes of People With Crohn's Disease (CD)

NCT05056441 ·Status: COMPLETED

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

NCT01224171 ·Status: COMPLETED ·Phase: PHASE3

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762 ·Status: COMPLETED ·Phase: PHASE4

A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

NCT04885920 ·Status: COMPLETED

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

NCT04989907 ·Status: COMPLETED